Skip to main content

IP Update: Apr 8, 2010

Premium

Title: RIP140 Regulation of Glucose Transport

Patent Number: 7,691,823

Filed: March 7, 2005

Lead Inventor: Michael Czech, University of Massachusetts (RXi Pharmaceuticals)

"Inhibition of RIP140 increases glucose transport," the patent's abstract states. "Compounds that inhibit RIP140 expression or activity are useful for treating disorders associated with aberrant glucose transport, treating obesity, increasing metabolism, and increasing brown fat."

The patent specifically claims the use of an siRNA to inhibit RIP140.


Title: Compositions and Methods for Inhibiting Expression of a Gene from the JC Virus

Patent Number: 7,691,824

Filed: April 27, 2007

Lead Inventor: Pamela Tan, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for inhibiting the expression of a gene from the JC virus, comprising an antisense strand having a nucleotide sequence which is less than 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC virus," the patent's abstract states. "The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC virus in a cell."


Title: In Vivo Production of Small Interfering RNAs that Mediate Gene Silencing

Patent Number: 7,691,995

Filed: July 12, 2002

Lead Inventor: Phillip Zamore, University of Massachusetts

"The invention provides engineered RNA precursors that, when expressed in a cell, are processed by the cell to produce targeted small interfering RNAs that selectively silence targeted genes using the cell's own RNA interference pathway," according to the patent's abstract. "By introducing nucleic acid molecules that encode these engineered RNA precursors into cells in vivo with appropriate regulatory sequences, expression of the engineered RNA precursors can be selectively controlled both temporally and spatially, i.e., at particular times and/or in particular tissues, organs, or cells."


Title: Functional and Hyperfunctional siRNA

Patent Number: 7,691,997

Filed: April 7, 2005

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes."


Title: siRNA Targeting Nucleoporin 62kDa

Patent Number: 7,691,998

Filed: June 9, 2008

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for Nup62."


Title: RNA Interference-Mediated Inhibition of NOGO and NOGO Receptor Gene Expression Using Short Interfering Nucleic Acid

Patent Number: 7,691,999

Filed: July 16, 2008

Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)

"This invention relates to compounds, compositions, and methods useful for modulating NOGO and/or NOGO receptor gene expression using short interfering nucleic acid molecules," according to the patent's abstract. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of NOGO and/or NOGO receptor gene expression and/or activity by RNA interference using small nucleic acid molecules. In particular, the … invention features small nucleic acid molecules … and methods used to modulate the expression of NOGO and/or NOGO receptor genes, such as NOGO-A, NOGO-B, NOGO-C, NOGO-66 receptor, NI-35, NI-220, NI-250, myelin-associated glycoprotein, tenascin-R, and NG-2."

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.